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ABSTRACT 
Background and Purpose: Doxorubicin (DOX) is an effective cancer therapeutic agent but causes 
therapy-limiting cardiotoxicity. The effects of DOX and its metabolite doxorubicinol (DOXL) on 
individual channels have been well characterised in isolation. However, it is unknown how the 
action and interaction of affected channels combine to generate the phenotypic cardiotoxic 
outcome. We sought to develop an in silico model that links drug effects on channels to action 
potential duration (APD) and intracellular Ca2+ concentration in order to address this gap in 
knowledge. 
Experimental Approach: We first propose two methods to obtain, from values reported in the 
literature, consensus drug effects on the currents of individual channels, transporters and pumps. 
Separately, we obtained equivalent values for APD and Ca2+ concentration (the readouts used as 
surrogates for cardiotoxicity). Once derived, the consensus effects on the currents were incorporated 
into established biophysical models of the cardiac myocyte and were refined adjusting the 
sarcoplasmic reticulum Ca2+ leak current (ILeak) until the consensus effects on APD and Ca2+ 
dynamics were replicated. Using factorial analysis, we then quantified the relative contribution of 
each channel to DOX and DOXL cardiotoxicity.  
Key Results: The factorial analysis identified the rapid delayed rectifying K+ current (IKr), the L-
type Ca2+ current (ICaL) and the sarcoplasmic reticulum Ca2+ leak current (ILeak) as the targets 
primarily responsible for the cardiotoxic effects on APD and Ca2+ dynamics.  
Conclusions and Implications: This study provides insight into the mechanisms of DOX induced 
cardiotoxicity and a framework for the development of future diagnostic and therapeutic strategies. 
 
Abbreviations 
AP, action potential; APD, action potential duration; DOX, doxorubicin; DOXL, doxorubicinol; IKr, 
rapid delayed rectifying K+ current; ICaL, L-type Ca
2+ current; ILeak, sarcoplasmic reticulum Ca
2+ 
leak current; INaK, Na
+/K+ pump current; INaCa, Na
+/Ca2+ exchange current; IRel, ryanodine receptor 
current; IUp, sarcoplasmic reticulum Ca
2+-ATPase pump current; SR, sarcoplasmic reticulum. 
 
INTRODUCTION 
Anthracyclines play an important role in the treatment of neoplastic cancers due to their efficiency 
and broad activity spectrum. Doxorubicin (DOX) is the predominant anthracycline, but its use is 
limited due to cardiotoxicity (Octavia et al., 2012).  
In humans, DOX cardiotoxicity manifests over two time scales: acute and chronic. Acute effects occur 
within 48 hours of infusion and are generally reversible and clinically manageable (Takemura & 
Fujiwara, 2007). They develop in up to 40% of the patient population and manifest as primary 
electrophysiological dysfunction: atypical ST-segment and T-wave abnormalities, reduced QRS 
voltages, sinus tachycardia, QT interval prolongation and ventricular and atrial arrhythmias (Octavia 
et al., 2012; Singal et al., 1987; Yeh et al., 2004). Chronic toxicity manifests as progressive 
hypotension, tachycardia with a characteristic decrease in the QRS voltage, cardiac dilatation and 
ventricular failure (Lefrak et al., 1973; Singal et al., 1987) and may not become evident until 4 to 20 
years after the last administration of DOX (Octavia et al., 2012). Chronic toxicity affects >60% of 
patients receiving maximal acceptable cumulative dosages (Dresdale et al., 1983) and has a poor 
prognosis (Octavia et al., 2012; Takemura & Fujiwara, 2007). This combination of electrical and 
mechanical dysfunction represents cellular electrophysiology and excitation-contraction coupling 
toxicity.   
Investigations on DOX toxicity mechanisms, whether after acute or chronic exposure, have made 
use of ex vivo isolated cardiac myocyte preparations. These studies have shown that changes in 
action potential (AP) (Wang et al., 2001; Wang & Korth, 1995) and Ca2+ handling dynamics (Sag et 
al., 2011; Wang et al., 2001; Wang & Korth, 1995)   in acute studies differ from outcomes after 
chronic exposure (Jensen, 1986; Shenasa et al., 1990). Based on this and the range of known effects 
on different relevant molecular targets, it can be surmised that acute and chronic DOX 
cardiotoxicity reflect a combination of direct DOX effects on channel, pump and exchanger 
function and indirect effects on expression levels, with the metabolite doxorubicinol (DOXL) which 
accumulates in cardiac tissue (Del Tacca et al., 1985) possibly contributing to the chronic toxicity 
(Olson & Mushlin, 1990). Unfortunately, although such a cause and effect matrix may be inferred, 
the mechanistic detail remains unclear. 
Quantifying drug effects on relevant molecular targets may help inform earlier diagnosis of toxicity 
and better targeted treatment. Previous studies have primarily focused on characterising drug effects 
on individual molecular targets. How such effects account for the changes in AP and Ca2+ 
homeostasis is a gap in knowledge. Biophysical models of cellular electrophysiology and Ca2+ 
dynamics (Fink et al., 2011) may provide a framework for bridging this gap.  
We have focused on modelling DOX and DOXL effects on electrophysiology and calcium handling. 
This is because these are important end effectors mediating adverse DOX and DOXL actions on 
rhythm and force. Changes in these effectors may be caused by direct drug-molecule interactions or 
may be secondary to known effects on mitochondrial DNA (Serrano et al., 1999), ROS production 
(Davies & Doroshow, 1986), the electron transport chain (Marcillat et al., 1989) and mitochondrial 
permeability (Montaigne et al., 2011). Whether the effects on ion channels and calcium handling are 
‘direct’ or ‘indirect’ does not affect the modelling results, which incorporates ‘end’ effects and 
concentrations without the need to specify whether or not the outcomes are directly or indirectly 
mediated. 
In this study, we modified two pre-existent mathematical models to investigate the contributions of 
different transporters, pumps and channels, hereafter called ‘channels’ when described collectively, 
to overall DOX and DOXL cardiotoxicity. The first task was to ensure standardization of the input 
data. Owing to the heterogeneity of the way drug effects are described in the literature, we 
undertook a parallel investigation to determine the best method to obtain a consensus drug effect on 
individual channels, APD and Ca2+ dynamics. The method of deriving and processing these effects 
is thus part of the study. Once derived, the consensus effect values for drug actions on channels 
were incorporated into biophysical models of cardiac myocyte electrophysiology and Ca2+ 
dynamics. We then refined the models until the consensus drug effect on APD and Ca2+ dynamics 
were replicated. Using factorial analysis, we then alternated the inclusion of individual consensus 
drug effects and their combinations to reveal the relative contribution of each channel, and their 
interactions, in mediating DOX and DOXL cardiotoxicity. 
The study shows that biophysical modelling can replicate DOX cardiotoxicity well in both human 
and rabbit models, with some caveats. Using the models we make three testable predictions. First, 
that acute DOX and DOXL and chronic DOX exposure will increase the sarcoplasmic reticulum 
(SR) Ca2+ leak (ILeak). Second, that reported increased K+ permeability in cells chronically exposed 
to DOX is consistent with an increase in rapid delayed rectifying K+ current (IKr). Third, that acute 
DOXL exposure is unlikely to cause inhibition of the Na+/Ca2+ exchanger (INaCa). 
 
METHODS 
Cell Models 
The bulk of the input data were from rabbit, and because of this, simulations were made for rabbit 
(Morotti et al., 2012) as well as human (ten Tusscher & Panfilov, 2006) models of cardiac 
ventricular myocyte electrophysiology and intracellular Ca2+ regulation. The independent variables 
in these models were the IKr, the L-type Ca
2+ current (ICaL), ILeak and currents associated with the 
Na+/K+ pump (INaK), SR Ca
2+-ATPase (IUp), INaCa (capable of operating in forward and reverse 
mode) and the ryanodine receptor (IRel). A full description of the model equations and parameters 
for both these models are available through the CellML repository 
(https://models.physiomeproject.org/workspace/49c) and were converted to C and MATLAB code 
through COR (http://opencor.ws/cor/) (Garny et al., 2003), now superseded by OpenCOR 
(http://opencor.ws). 
In these models, the general form of the current through a given channel is as follows: 
𝐼𝑖 = 𝐺𝑖(𝑉 − 𝑉𝑖)    (1) 
where 𝐼𝑖 is the current through the channel, 𝐺𝑖 is the channel conductance, 𝑉 is the membrane 
potential and 𝑉𝑖 is the Nernst potential for the channel.  
The models simulate changes in currents during a simulated electrical field stimulation to generate 
values for AP and intracellular Ca2+ concentration. AP duration (APD) was expressed as ms at 90% 
repolarization and intracellular Ca2+ concentration was expressed as an absolute value at the systolic 
peak. We also determined the time in ms taken for the Ca2+ concentration to recover to 10% of its 
peak value (Ca2+ relaxation time), a variable that has been used in published literature as an index of 
recovery of diastolic Ca2+ concentration (Wang et al., 2001).  
Drug Effects 
The models allow variation in the influence of each current on AP and intracellular Ca2+ 
concentration, by using an 𝛼 factor as follows: 
𝐼𝑖 = 𝛼𝑖𝐺𝑖(𝑉 − 𝑉𝑖)   (2) 
where 𝛼𝑖 is the consensus value for the effect of DOX (or DOXL) on each current. 
Drug-induced changes in APD, systolic Ca2+ concentration and Ca2+ relaxation time were expressed 
as a % change from control values generated with  = 1. 
The consensus values of 𝛼, % change of APD, % change of systolic Ca2+ concentration and % 
change of Ca2+ relaxation time were determined by searching PubMed using the following 
keywords: doxorubucin, adriamycin, doxorubicinol, calcium, action potential, myocyte, ion 
currents, channels, pump, exchanger. Data selected for acute exposure of DOX and DOXL 
modeling were limited to cells exposed to the drug in vitro for up to 180 minutes. Data selected for 
simulating the chronic DOX exposure were limited to cells from hearts removed from subjects 
exposed chronically in vivo to DOX for a minimum of 1 week and a maximum of 9 weeks. These 
measurements reflect the combined effects of DOX and DOXL, which will both be present in the 
biophase, and their combined effects on protein targets are used to constrain the model. In studies 
where surrogate readouts of channel function were reported, these were treated as equivalent to 
direct measures. In the specific case where changes in channel mRNA expression were the primary 
information source, the fold change in mRNA between drug exposure and control was used as an 
estimate of the drug effect on function. The volume of available human tissue data was found to be 
insufficient for our purposes. Therefore, all data used to determine consensus effects were derived 
from dog, rabbit, guinea pig and rat. To avoid bias, no exclusion criteria based on data 
completeness, provenance or quality, were used with a single exception: rat data on APD was not 
included since rat ventricular APD is distinctively unrelated to IKr (Rees & Curtis, 1996). 
We discovered that experimental methods and data reporting are very heterogeneous. Consequently, 
we evaluated two different methods for estimating the consensus effects of DOX and DOXL, i.e., 
values of , % change of APD, % change of systolic Ca2+ concentration and % change of Ca2+ 
relaxation time. 
Method 1 
The first approach was based on an assumption that the maximum concentration used in a given 
study is the concentration causing the maximum effect on each given target. The values thus 
obtained therefore have accuracy but uncertain precision.  
A single % change 𝛼 value was calculated for each channel as the mean of the % change values 
reported from different studies rounded to the nearest 10%, ranging between 0.1 and 0.9 to 
represent a % change between 10% and 90% (Table 1, column 2). We used a similar approach when 
calculating the consensus values for the % change in APD, systolic Ca2+ concentration and Ca2+ 
relaxation time (Table 2, column 2). 
This approach allows for the fact that a given drug concentration may have different effects in 
different preparations. However, this method disregards the concentration dependence of drug 
effects. 
Unlike the α value for all other targets, the α value for ILeak was fitted to achieve the consensus 
cellular Ca2+ transient and was not inferred from direct experimental measurements of ILeak. This 
parameter is a prediction of the modelling framework and not an experimental measurement. The 𝛼 
for ILeak is calculated as the factor needed for the simulated % systolic Ca2+ concentration to match 
the consensus % systolic Ca2+ concentration, with  bounded to fall between 2 and 10, representing 
a % increase ranging between 100% and 900%. Some qualitative data are available (Sag et al., 
2011; Wang & Korth, 1995)  that indicates a likely effect of DOX on this current, but no reliable 
quantitative values are available to date. 
Method 2 
The second approach was based on a different assumption: that drug inhibition or activation of each 
channel can be described by a Hill equation with no co-operativity, with the maximum effect of the 
drug (Emax) equalling 100% inhibition or a 100% increase. The values obtained have precision, but 
uncertain accuracy. The resulting scalars are given as: 
channel activity =
1
1+(
[drug]
IC50
)
Hill ,      channel activity =
1
1+(
EC50
[drug]
)
Hill  (3) 
where IC50 or EC50 corresponds to the drug concentration that causes 50% inhibition or activation, 
respectively, [drug] is the concentration of the drug and Hill is the co-operativity parameter which is 
set to 1.  
This approach allows EC50 or IC50 values to be estimated for all channels (Table 1, column 4-5; 
Table 2, column 3-4), even in cases where only a single data point was available.  From this we 
were able to construct Hill plots that permitted estimation of % change in 𝛼 after exposure to 100 
µM of DOX and 10 µM of DOXL by extrapolation (Table 1, column 3). These concentrations were 
selected because they are direct counterparts of the concentrations most commonly evaluated in 
‘wet’ tissue studies (Table 1 and Table 2, column 6). This method was not applied to estimate 
consensus values of % change of APD, systolic Ca2+ concentration and Ca2+ relaxation time as the 
concentrations in these studies are predominantly consistent with the chosen concentrations of 100 
µM of DOX and 10 µM of DOXL. 
The α values for ILeak were estimated for the case of 100 µM of DOX and 10 µM of DOXL by first 
simulating the effect of DOX or DOXL to permit determination of an α value for ILeak, which was 
inferred by fitting the model predictions of Ca2+ concentration to experimental measurements of 
Ca2+ concentration when cells were exposed to either 100 µM of DOX and 10 µM of DOXL. This 
gave α values for ILeak for 100 µM of DOX and 10 µM of DOXL. 
Chronic DOX exposure was not evaluated by this approach since changes in current activity 
develop over time and are not dose dependent in the classical sense owing to their genomic basis, 
and therefore not appropriately represented by a simple mass action model.  
Provenance of Input Data and Methods for Best Estimation 
The processes described above for determining consensus values were difficult to execute in certain 
cases. These cases included data that lacked precision (too few studies and/or semi quantitative 
estimates), or accuracy (several studies reporting contradictory estimates) as described below. 
Estimates of % change of systolic Ca2+ concentration after acute DOX exposure 
The change in systolic Ca2+ concentration caused by acute DOX exposure varies, with some authors 
reporting a decrease whilst others report an increase, e.g., Sag et al. (2011) reported a decrease of 
43% whereas Wang & Korth (1995) reported a 50% increase. This inconsistency in response is also 
reflected in inotropy measurements which are equally inconsistent (De Beer et al., 2001). The +50% 
value was chosen as the consensus effect because the drug concentration used in this study (100µM) 
was the same as the reference concentration used in the acute DOX simulation. 
Estimates of % change of Na+/Ca2+ exchanger inhibition after acute DOXL exposure 
Acute DOXL has been reported to cause up to 100% inhibition of the Na+/Ca2+ exchanger (Table 1, 
column 2) (Boucek et al., 1987a) but when this effect was incorporated into the human and rabbit 
models the outcome was asystole due to failure of repolarisation. It is difficult to explore this 
observation further since the study (Boucek et al., 1987a)  did not state whether the measurements 
were corrected for changes in intracellular Na+ due to Na+/K+ pump inhibition.  
In view of the potential importance of this, and the meagre provenance of the source data (Boucek 
et al., 1987a), we conducted a separate simulation to test if the reported 100% inhibition of the 
Na+/Ca2+ exchanger could be explained by the secondary effect of intracellular Na+ accumulation 
following the Na+/K+ pump inhibition by DOXL. To do this, we simulated the recovery of Ca2+ 
concentration following a caffeine exposure (a Na+/Ca2+ exchanger-dependent process (Bers, 2000)) 
for the human cell model, with the Na+/K+ pump set at 50% (Table 1, column 2). This revealed that 
the published inhibition of the Na+/Ca2+ exchanger can be explained by the inhibitory effects of 
accumulation of intracellular Na+ due to Na+/K+ inhibition. For this reason, we deduced that DOXL 
has a negligible direct effect on the Na+/Ca2+ exchanger and set 𝛼 to 1 in the simulations that follow 
below. 
Estimates of % change of APD after chronic DOX exposure 
Chronic DOX experiments are fewer and the resultant 𝛼 estimates are therefore less reliable than 
those for acute DOX exposure. Indeed, reported effects on APD are conspicuously inconsistent, 
with changes ranging from an increase of 10% (Milberg et al., 2007) to a decrease of ~20% 
(Doherty & Cobbe, 1990; Shenasa et al., 1990). We selected a -20% value as the consensus acute 
effect on APD.  
Estimates of 𝛼 value for IKr after chronic DOX exposure 
Chronic DOX increases K+ permeability (Shenasa et al., 1990) but the channel responsible has not 
been identified. We represented this qualitative observation by assuming, in the first instance, a 50% 
activation of the most commonly drug-affected repolarizing K+ current, IKr. The limitations of this 
assumption are revisited in the Discussion. 
Estimates of % change of systolic Ca2+ concentration after chronic DOX exposure 
Data on effects of chronic DOX exposure on Ca2+ concentration suggest longer exposures cause an 
increase (Kapelko et al., 1996; Szenczi et al., 2005)(Kapelko et al., 1996; Szenczi et al., 2005) and 
shorter exposures cause a decrease (De Angelis et al., 2010).  This may reflect chronic DOX 
causing a decrease in intracellular Ca2+ that gives rise to heart failure which then leads to Ca2+ 
accumulation (Olson & Mushlin, 1990) that is not seen with acute exposure.  
As we are primarily interested in DOX toxicity, we aimed to simulate the decrease in Ca2+ 
concentration attributed to chronic DOX exposure (which has been examined only in rats to date). 
The idea of a decrease resonates with data from humans in which heart failure caused by chronic 
exposure to DOX has been associated with a depressed contractile state (Singal et al., 1987), which 
would be consistent with a reduction in Ca2+ concentration. 
Simulations 
The 𝛼 values from method 1 were incorporated into human and rabbit models described above, and 
the resulting models labelled as acute DOX, chronic DOX and acute DOXL. Separately the 𝛼 
values from method 2 were incorporated and the models labelled as acute 100 µM DOX and acute 
10 µM DOXL. 
The field stimulation protocol used to generate APs consisted of 3,000 depolarizations at 1 Hz. This 
ensures equilibrium and is based on physiological and standard experimental pacing rate (Wang et 
al., 2001). APD, systolic Ca2+ concentration Ca2+ and relaxation time values for analysis were 
generated from the 3,001st depolarization.  
We then compared the generated % change of APD, systolic Ca2+ concentration and relaxation time 
with the consensus values of the % change of APD, systolic Ca2+ concentration and Ca2+ relaxation 
time observed in experimental studies (Table 2, column 2). We then modified the consensus value 
of 𝛼 for  𝐼𝐿𝑒𝑎𝑘 (the explanation for this is given later) until we recapitulated the consensus % change 
values. A synopsis of predicted model function at different pacing rates for the final fitted models is 
provided in the online supplement. 
Factorial Analysis 
The overall process of computation ended with factorial analysis. APD, systolic Ca2+ concentration 
and Ca2+ relaxation time were generated by simulation with 𝛼 values defined either as 1 (drug free 
simulation) or equal to the consensus values derived by method 1 and then by method 2 (consensus 
altered simulation values). All combinations of 𝛼 values (drug free and consensus altered value) 
were examined, thus revealing independent contributions of currents on APD, systolic Ca2+ 
concentration and Ca2+ relaxation. Current-current interactions were also considered by introducing 
simultaneous changes of 𝛼 values in pairs of currents. 
RESULTS 
Acute DOX effects assessed by method 1 
Rabbit  
The APD, Ca2+ concentration and Ca2+ relaxation time were initially +4%, +174% and -1%, 
respectively, when there is no increase in the SR leak (𝛼 = 1 for ILeak). Increasing the SR leak flux 
by +300% (𝛼 = 4 for ILeak) caused the effect of simulated acute DOX on APD, Ca2+ concentration 
and Ca2+ relaxation time to be +7%, +23% and +17%, respectively, compared to consensus values 
of +50%, +50% and +30%, respectively (Figure 1, Table 2 and Table 3).  
Human 
The APD, Ca2+ concentration and Ca2+ relaxation time were initially +15%, +141% and +41%, 
respectively, when there is no increase in the SR leak (𝛼 = 1 for ILeak). Increasing the SR leak flux 
by +100% (𝛼 = 2 for ILeak) caused the effect of simulated acute DOX on APD, Ca2+ concentration 
and Ca2+ relaxation time to be +13%, +47% and +58%, respectively, compared to consensus values 
of +50%, +50% and +30%, respectively (Figure 1, Table 2 and Table 3). 
Acute DOXL effects assessed by method 1 
Rabbit 
Estimates of APD, Ca2+ concentration and Ca2+ relaxation time were -28%, +11% and +44%, 
respectively. Since these values digress from the consensus values of -30%, -20% and +50%, 
respectively, leak flux was then increased by +900% (𝛼 = 10 for ILeak). Consequently, APD, Ca2+ 
concentration and Ca2+ relaxation time became -24%, -29% and +57%, respectively, in closer 
agreement with the consensus values shown above (Figure 1, Table 2 and Table 3). 
Human 
Estimates of APD, Ca2+ concentration and Ca2+ relaxation time were -32%, -14% and +13%, 
respectively. Leak flux was then increased by +100% (𝛼 = 2 for ILeak) and APD, Ca2+ concentration 
and Ca2+ relaxation time became -38%, -38% and +18%, respectively, in closer agreement with the 
consensus values of -30%, -20% and +50%, respectively (Figure 1, Table 2 and Table 3). 
Chronic DOX effects assessed by method 1 
Rabbit 
Effects of chronic DOX on SR leak were set at +300% (𝛼 = 4 for ILeak) in the rabbit model. The 
inclusion of these changes caused APD, Ca2+ concentration and Ca2+ relaxation time determined by 
method 1 to change from -14%, +87% and -13% to -11%, -12% and +9%, consistent with 
consensus values of -20%, -55% and +10%, respectively (Figure 1, Table 2 and Table 3). 
Human 
Effects of chronic DOX on SR leak were set at +200% (𝛼 = 3 for ILeak) which caused APD, Ca2+ 
concentration and Ca2+ relaxation time determined by method 1 to change from -1%, +84% and 
+17% to -7%, -38% and +3%, consistent with consensus values of -20%, -55% and +10%, 
respectively (Figure 1, Table 2 and Table 3). 
Acute DOX effects assessed by method 2 
Rabbit 
Method 2 predicted DOX-induced changes in APD, Ca2+ concentration and Ca2+ relaxation time, of 
+18%, +84% and -6% in rabbit, values that digress from the consensus values of +50%, +50% and 
+30%, respectively. When leak flux was increased by +100% (𝛼 = 2 for ILeak) changes were +19%, 
+48% and +0%, respectively, in closer agreement with consensus values (Figure 1, Table 2 and 
Table 3).  
Human 
Method 2 predicted DOX-induced changes in APD, Ca2+ concentration and Ca2+ relaxation time, of 
+12%, +90% and +10%. When leak flux was increased by +100% (𝛼 = 2 for ILeak), changes were 
+11%, +13% and +20%, respectively, in good agreement with consensus values +50%, +50% and 
+30%, respectively (Figure 1, Table 2 and Table 3).  
Acute DOXL effects assessed by method 2  
Rabbit 
Method 2 predicted DOXL-induced changes in APD, Ca2+ concentration and Ca2+ relaxation time of 
-27%, +23%, +37% (rabbit) respectively. After leak was increased by +900% (𝛼 = 10 for ILeak) 
values changed to -24%, -28% and +47%, respectively, in better agreement with consensus values 
of -30%, -20% and +50%, respectively (Figure 1, Table 2 and Table 3). 
Human 
Method 2 predicted DOXL-induced changes in APD, Ca2+ concentration and Ca2+ relaxation time of 
-30%, +6%, +7%, respectively. After leak was increased by +100% (𝛼 = 2 for ILeak), values changed 
to -37%, -26%, and +13%, respectively, in closer agreement with consensus values of -30%, -20% 
and +50%, respectively (Figure 1, Table 2 and Table 3).   
Factorial Analysis 
We undertook factorial analysis on data for the human model only (Figure 3 and Table 4) having 
found that the simulation of drug effects in rabbit and human models were comparable (Figure 4).  
Factorial analysis effects are expressed as % values (referring to the size of the change attributable 
to the current, or current interactions). We first considered the acute effects of DOX using method 1. 
In this case, the current with the greatest role in the effect of DOX on APD (method 1) was ICaL 
(+7%) followed by IKr (+5%), with IUp, ICaL, INaCa and ILeak having the largest role in the effect on 
Ca2+ concentration (-81%, +70%, -67% and -88%, respectively). IUp had the largest role in the effect 
on Ca2+ relaxation time (+31%). Interactions with maximum role in the effect were ICaLxINak (1%), 
INaCaxILeak (1%) and INakxILeak (1%) for APD, IUpxILeak (23%) and IUpxINaCa (21%) for Ca2+ 
concentration and IUpxINaCa (7%) and INaCaxILeak (6%) for Ca2+ relaxation time. All interactions for 
APD were negligible (<1%). 
Method 2 outcomes were similar to method 1 outcomes. The current with the greatest role in the 
effect of DOX on APD using method 2 was ICaL (+5%) followed by IKr (+6%), with ICaL and ILeak 
having the most substantial role in the effects on Ca2+ concentration (+50% and -72%, respectively). 
In contrast, Ca2+ relaxation time was affected by ILeak only (+15%). Interactions with maximum 
roles in the effect were ICaLxILeak (1%) and IRelxILeak (1%) for APD, ICaLxILeak (13%) for Ca2+ 
concentration and IRelxILeak (3%) for Ca2+ relaxation time. All interactions for APD were negligible 
(<1%). 
Next, we considered acute effects on DOXL. In method 1, changes in APD were predominantly 
determined by effects on INaK, IUp, IKr and ILeak (-15%, -9%, -7% and -6%, respectively), with effects 
on INaK, IUp and ILeak contributing the most to changes in Ca2+ concentration (+145%, -113% and -
79%, respectively) and changes in Ca2+ relaxation time (-13%, +24% and +9%, respectively). 
Interactions with maximum influence were effects on IUpxINaK (7%) for changes in APD, effects on 
IUpxINaK (85%) for changes in Ca2+ concentration and effects on IUpxILeak (8%) for changes in Ca2+ 
relaxation time. 
In method 2, acute effects of DOXL exposure were accounted for by actions on targets that are in 
close agreement with findings for method 1, with effects on INaK, IUp, IKr and ILeak (-14%, -8%, -7% 
and -7%, respectively), INaK, IUp and ILeak (+161%, -118% and -87%, respectively) and INaK, IUp and 
ILeak (-13%, +18% and +9%, respectively) having the major role in the effects on APD, Ca2+ 
concentration and Ca2+ relaxation time, respectively. Interactions with maximum influence were 
IUpxINaK (7%) for APD, IUpxINaK (82%) for Ca2+ concentration and IUpxINaK (5%) for Ca2+ relaxation 
time. 
Finally, we considered effects of chronic DOX exposure. Here, effects on IKr (-6%), ICaL (+5%) and 
ILeak (-4%), played the predominant role in changes in APD (similar to findings for effects of acute 
DOX exposure). Effects on ICaL and ILeak had the major contribution to changes in Ca2+ 
concentration (+46% and -109%, respectively) whilst effects on INaCa and ILeak had the greatest 
contribution to changes in Ca2+ relaxation time (+9% and +13%, respectively). Interactions having 
the greatest contribution to effects were INakxILeak (1%) for APD, ICaLxILeak (23%) for Ca2+ 
concentration and IRelxILeak (10%) for Ca2+ relaxation time. All interactions for APD were negligible 
(<1%). 
Testing Model Assumptions 
While the effects of DOX on the heart have been studied extensively, we have shown that these 
measurements are very heterogeneous spanning a broad range of species, preparations and 
temperatures. We have proposed and applied two frameworks for quantitatively combining 
heterogeneous pharmacological data. However a number of assumptions, indirect inferences and 
simplifications were required to combine all of the experimental data. Here we have performed 
additional simulations to interrogate whether these assumptions are robust.  
Acute DOX causes a decrease in heart rate (Suzuki et al., 1997). To explore whether bradycardia 
affects the modelling we imposed a large reduction in rate (to 0.5 Hz) and found a range of 
modifications in outcome. There was no particular pattern within or between human and rabbit 
comparisons. However, given that the derived default model used 1Hz stimulation (for reasons 
explained) and yet 1 Hz is severely bradycardic for rabbit while normal for human, and given that 
baseline Ca2+ and Na+ values are highly heart rate dependent, and this dependence is species related, 
it is no surprise that the effects of this severe bradycardia differed from setting (e.g. acute DOX, 
human) to setting (e.g., chronic DOX, rabbit) (Table 5).   
In the online supplement we present the frequency dependence of drug effects in the human and 
rabbit models. Frequency did not qualitatively effect the model results (e.g. for acute DOX APD, 
peak Ca+ and Ca2+ RT all increased). However, for a number of models there was a marked impact 
on diastolic Ca2+ and intracellular Na+ frequency response. In the majority of cases there is no 
reverse rate dependence, the exception being the DOX 100μM rabbit model. There are insufficient 
wet biology data sets to examine these model predictions, and whether they reflect outcomes in 
human or rabbits will require experimental validation. 
The level of INaCa inhibition in the simulations of acute exposure to DOX was derived from a 
combination of the available experimental measurements from the three relevant publications. Two 
values were from rabbit and one was from canine studies (Table 1). Considering the mean of only 
the rabbit measurements would give an inhibition of INaCa of 10% instead of the original 40% 
consensus value derived from the mean of the three studies. The simulation outcomes for rabbit are 
not strongly affected by the level of INaCa inhibition (Table 5). However, in the human model, while 
the effect of DOX on APD remained unchanged, the level of INaCa inhibition by DOX did affect the 
Ca2+ transient (Table 5). This may be due to the greater increase in SR leak flux in the rabbit model 
resulting in an already attenuated Ca2+ transient that is less dependent on INaCa.  
Estimations for DOX inhibition of IKr were based in part from guinea pig measurements performed 
by Wang and Korth (1995) who found that DOX caused a 40% inhibition of what they called ‘IK’. 
Because IKs is up to ten times larger than IKr in guinea pigs (Sanguinetti & Jurkiewicz, 1990) it 
cannot be assumed that the Wang and Korth effects are entirely attributable to IKr block (these 
investigators used tail current as their readout and the work was done before it was mandatory to 
disentangle IKr from IKs) meaning that relying on their data alone may overestimate the effect of 
DOX on IKr. Fortunately, in an expression system Ducroq et al. (2010) reported that DOX had an 
IC50 for IKs of ~5μM and limited inhibition of IKr at a DOX concentration of 30μM. With these two 
(albeit limited) estimates of effects, we tested the impact of potentially over estimating DOX effects 
on IKr by running simulations with the α value of IKr set to -30%, -20% and -10%. The results are 
presented in Table 5. In all simulations decreasing the inhibition of IKr decreased the prolongation 
of the APD, making the model less able to recapitulate the experimentally measured effects of DOX 
on APD. To test if blocking IKs as opposed to or in combination with IKr alters the predicted effect 
of DOX, we simulated the impact of IKr and IKs inhibition in the DOX 100μM model in two 
simulations. First we assumed that IKr was not inhibited by DOX and that IKs inhibition has an IC50 
of 5μM. In the second simulation we assumed IKr had an IC50 of 100μM (significantly larger than 
30μM and causing a -50% inhibition of IKr inferred from Wang and Korth (1995)) and IKs had an 
IC50 of 5μM. The predicted effects on cellular function are reported in Table 5 and show that all 
combinations of possible K+ channel inhibition due to acute DOX exposure predict changes in APD 
and the Ca2+ transient consistent with consensus values. 
The input data for IKr effects in the simulations of chronic DOX relied on potassium permeability 
data (Shenasa et al., 1990) as a surrogate since no direct data on IKr exists. We made the assumption 
that chronic DOX caused an increase of IKr of +50%. To test the impact of this assumption we 
performed simulations with the α value for IKr varying from 0% and +25% and reported the results 
in Table 5. Although this decreased the ability of the simulations to predict DOX effects on APD 
and Ca2+ concentration the changes were small, indicating that the uncertainty in this parameter is 
unlikely to alter our study conclusions. 
 
DISCUSSION 
In this study we showed for the first time that it is possible for two well-known mathematical 
models of rabbit and human ventricular electrophysiology, when provided with appropriate scaling 
factors, to replicate the consensus effects of acute DOX, chronic DOX and acute DOXL exposure 
on APD, systolic Ca2+ concentration and Ca2+ relaxation time. The consensus values were 
determined using a novel combination of two different methods. Reassuringly, they generated 
similar predictions of the drug effect on APD, Ca2+ concentration and Ca2+ relaxation time. 
The process of model development identified the need to introduce drug effects on the SR Ca2+ leak 
to recapitulate observed drug induced changes in cellular function, including the increase in K+ 
permeability following chronic DOX exposure that is consistent with DOX effects on IKr, and also 
showed that acute DOXL exposure is unlikely to inhibit INaCa. 
Using the models we quantified the relative contributions of drug effects on each target to the toxic 
phenotype. Consideration of the scaling factors revealed that the consensus drug effects were 
different for simulation of acute DOX, compared with chronic DOX and acute DOXL exposure. 
 
INaCa inhibition  
The modelling indicates that reports that INaCa is inhibited by DOXL (Olson et al., 1988)  by up to 
100% may not be correct (or, at least, relevant to the clinical use of the drug, owing perhaps to the 
selection of inappropriately high drug concentrations for study, an issue revisited at the end of the 
discussion). Unfortunately, it is not possible to interrogate this in detail since Boucek et al (1987a). 
did not reveal whether the effects of elevated intracellular Na+ that result from DOXL inhibiting the 
Na+/K+ pump were accounted for. Our simulation of Ca2+ concentration following a caffeine 
exposure and inhibition of the Na+/K+ pump (Figure 2) suggests the increase in Na+ would inhibit 
the activity of the Na+/Ca2+ exchanger and therefore we cannot assume that, in a functioning cell, 
the effects of DOXL on the Na+/Ca2+ exchanger current would result exclusively from direct effects. 
SR Leak 
The introduction in the modelling of an increase in SR leak due to DOX and DOXL allowed the 
models to replicate consensus APD and Ca2+ ‘wet’ values. The estimated increase in SR leak was 
approximated from qualitative observations (Sag et al., 2011; Wang & Korth, 1995)  and is 
potentially due to an increase in reactive oxygen species production that is known to increase SR 
leak (Bers, 2014) an effect caused by DOX (Octavia et al., 2012; Terentyev et al., 2008) . 
The SR leak was fitted to achieve the experimentally observed change in systolic Ca2+ 
concentration. In the acute DOX studies, systolic Ca2+ was reported to increase and decrease in two 
different publications. We choose the 50% increase in Ca2+ as the consensus value as it was 
recorded at the reference DOX concentration (100µM). Had we aimed to fit the SR leak to achieve 
a 40% decrease in systolic Ca2+ the magnitude of SR leak would have needed to be increased even 
further, indicating that the current estimates of increase SR leak flux may be conservative. 
The wide range of SR leak predicted by the model may reflect true differences in leak for different 
drugs under different conditions. The magnitudes, 2-10 fold, are within the range of reported 
changes in SR leak or surrogate measures in response to pharmacological agents, disease and in 
genetic models. (~2-6 fold) (Kohlhaas et al., 2006; Terentyev et al., 2008). At the same time the SR 
leak was inferred to maximise the similarity between the model predictions and experimentally 
observed cellular readouts. This means that all uncertainty and error in the drug effects on all the 
channels will be accumulated in this fitted parameter. This has the potential to increase the 
variability in the absolute magnitude of the change in the leak, however, the consistent qualitative 
finding of increased leak flux supports this model prediction. 
APD  
DOX and DOXL are known to affect multiple channels after exposure to acute DOX  
(Boucek et al., 1987a; Boucek et al., 1987b; Caroni et al., 1981; Earm et al., 1994; Miwa et al., 
1986; Mushlin et al., 1993; Olson et al., 1988; Qing et al., 1991; Sag et al., 2011; Wang & Korth, 
1995), chronic DOX (Arai et al., 1998; Dodd et al., 1993; Huang et al., 2003; Keung et al., 1991; 
Olson et al., 2005; Shenasa et al., 1990)and acute DOXL (Boucek et al., 1987a; Boucek et al., 
1987b; Mushlin et al., 1993; Wang et al., 2001). However, we found that not all effects are 
important for determining the cardiotoxicity.  
The factorial analysis revealed that actions on IUp, INaK, IKr and ILeak were responsible for the 
majority of acute DOXL effects on APD, whereas actions on IUp, INaK and ILeak resulted in the 
changes in systolic Ca2+ concentration. In contrast, actions on ICaL and IKr were identified as the 
principal determinants of the effects of acute and chronic DOX on APD, with ILeak also affecting the 
APD in chronic DOX. Actions on ICaL and ILeak were identified as the principal determinants of their 
effects on systolic Ca2+ concentration in acute and chronic DOX, with IUp and INaCa also having an 
effect in acute DOX. This analysis therefore identifies IKr, ICaL and ILeak as the channels to be 
targeted for preventive intervention or early detection of DOX cardiotoxicity, with IUp and INaK also 
relevant owing to the effects of DOXL. 
The importance of effects on multiple ion currents, specifically IKr and ICaL, in determining changes 
in APD is consistent with findings from previous modelling (Mirams et al., 2011) and single cell 
experimental studies(Kramer et al., 2013).  
We showed that DOX- and DOXL-induced increases in 𝛼 for ILeak were necessary for optimal 
predictiveness, regardless of the model. In all cases the increased leak depleted the SR of Ca2+ and 
lowered the systolic Ca2+ concentration. Additionally, and importantly, it also caused a shortening of 
the APD (Table 4). This may explain the counterintuitive finding that these IKr blocking drugs 
shorten APD (see above). ILeak does not act directly on the transmembrane potential but due to the 
decrease in SR load and the subsequent decrease in systolic Ca2+ concentration there will be a 
decrease in INaCa flux that in turn shortens the APD (Janvier & Boyett, 1996).  
INaK was found to play a role in the APD effects of acute exposure to DOXL. Inhibition of INaK 
causes an increase in intracellular Na+ concentration reducing the electrochemical gradient driving 
Ca2+ entry via INaCa. accounting for the positive inotropic effect of INaK blockade (Altamirano et al., 
2006) and the known effects of acute DOXL (Bueno-Orovio et al., 2014) on Ca2+ and APD (Table 
4).  
The large changes in 𝛼 for IRel (Table 1, column 2) did not account for the acute or chronic DOX 
effects on APD or systolic Ca2+ concentration. The inability of IRel to change the Ca2+ concentration 
is as predicted from other studies (Eisner et al., 2013) and can be explained by the fact that 
increasing or decreasing IRel will cause a subsequent decrease or increase in SR Ca2+ uptake which 
in turn functionally antagonises the effect of changes in IRel on Ca2+ concentration. 
Role of effects of DOXL in mediating the effects of chronic DOX exposure  
The metabolism of DOX under clinical conditions to produce DOXL means that the heart will be 
exposed to both compounds, albeit in concentrations that will vary in absolute terms and in terms of 
concentration ratios, both in the short term (over a day) and in the long term. We have not simulated 
the dynamic changing exposure of the heart to DOX and DOXL concentrations nor have we 
attempted to model a specific DOX to DOXL absolute or relative concentration. However, to create 
a representative simulation of chronic DOX exposure we combined multiple measurements 
(unavoidably derived from different species) exposed to 1 to 9 weeks of DOX. To examine which of 
the two compounds is likely to exert the dominant effect on any variable, we compared individual 
effects for in-vivo DOX exposure with the individual effects for in-vitro DOX and DOXL exposure 
(Fig. 3). 
Our modelling study predicts that despite the similarity between chronic DOX and acute DOXL 
models in terms of changes in APD and systolic Ca2+ concentration (Figure 1), their effects on 
individual channels appear to be different (Figure 3). This means that DOXL accumulation is 
unlikely to explain the toxicity of chronic DOX exposure, consistent with the findings of Mushlin et 
al. (Mushlin et al., 1993). Likewise, the effect of acute DOX and chronic DOX on channels is 
similar yet they have different effects on APD and systolic Ca2+ concentration (Figure 3). This 
finding suggests studying the effects of acute DOX could be useful for predicting the toxic effect of 
the chronic exposure to DOX.  
Clinical relevance  
In order to interrogate the clinical relevance of the findings, it is useful to consider concentration-
dependence. However, the pertinent concentration may not be the plasma concentration, owing to 
possible accumulation of drug inside cells and other factors.  
The range of acute DOX  IC50/EC50 values for channel effects derived from cellular preparations 
from the literature were between 29 and 7251 µM (Table 1, column 4), while the IC50 values 
derived for DOX for IKs in an expression system were ~5 µM, and the equivalent derived values for 
effects on APD, systolic Ca2+ concentration and Ca2+ relaxation time were 92 to 233 µM (Table 2, 
column 3, with one published value (Sag et al., 2011) excluded as explained). Similarly, estimates 
of DOXL IC50 and EC50 values were 8 - 240 µM for channel effects and 30 - 92 µM for effects on 
APD, systolic Ca2+ concentration and Ca2+ relaxation time (Table 1, column 4 and Table 2, column 
3, respectively).  
The DOX peak plasma concentrations in the clinical setting are reported as 1 - 10 µM (Barpe et al., 
2010; Cummings & Smyth, 1988; Gianni et al., 1997) and the equivalent value for DOXL is 0.2 µM 
(Cummings & Smyth, 1988). With the exception of reported IKs inhibition (Ducroq et al., 2010), 
these plasma levels are somewhat lower than those required to obtain channel effects and actions on 
APD, Ca2+ concentration and Ca2+ relaxation time, according to the experimental pharmacology 
literature. One explanation for this mismatch is that the acute cardiac toxicity associated with DOX 
in vivo may not be attributable to the acute ion channel effects. Alternatively, intracellular drug 
accumulation may be the primary determinant of the cardiotoxicity, as suggested previously (Olson 
et al., 1974), meaning that plasma concentration may not be indicative of the active concentration. 
A third explanation is the possible existence of an unknown DOX metabolite that accounts for the 
toxicity. Finally, the low IC50 value reported for IKs (compared with reported IC50 values for other 
targets) raises the possibility that IKs block is the primary contributor to acute DOX toxicity. In the 
online supplement we provide reference simulations of IKr inhibition alone or IKs inhibition alone in 
the human and rabbit models. For a 50% inhibition of IKs, (occurring at a clinically relevant drug 
concentration), the rabbit model shows negligible effects (all changes <3%). In contrast the human 
model shows a much larger response (changes range from 5-28%). It would appear from these 
findings that the role of IKs in mediating some of DOX’s cardiotoxicity may have been 
underestimated, and our recommendation would be that this be given more consideration going 
forward.   
We should note that plasma concentrations after a single dose do not give insight into the 
concentration-dependence of chronic toxicity.  
In summary, the present findings illustrate that the majority of published data on DOX and DOXL 
IC50/EC50 values for individual channels and none of the cellular function IC50/EC50 values directly 
relate to macro cardiac toxicity in terms of concentration dependence. This is not likely to be 
resolved until an exact matching data set of in vivo and channel actions is available, one in which 
exposure times are identical, and free drug concentrations and cell accumulation over time are 
better characterised. Nevertheless, the models provide a novel tool for linking channel effects to 
cellular phenotypes, despite the limitations inherent to the data. This study is therefore a first step 
towards linking channel effects to multi-scale emergent cellular phenotypes. 
Limitations and Future directions 
A novel combination of two proposed data integration methodologies was proposed to provide a 
rational framework for data integration. In the current version we treat each experimental read out 
as independent and ignore the variability of measurements. Specifically, we have not made any 
assumptions about whether two or more observations derive from a single protocol or separate 
protocols, and we do not place more weight on measurements that are less variable. This is 
exemplified by the acute effects of DOX on ICaL where Wang and Korth (1995) report a mean 21% 
increase in ICaL. However, when the mean changes were interpreted in the context of the variation in 
the experimental measurements, they were reported to not be statistically significant (Wang and 
Korth, 1995). Further, while reporting no significant change in ICaL Wang and Korth, (1995) these 
investigators reported a significant increase in peak Ca2+ concertation and APD. Hence, while we 
include the values from this study, our approach does not necessarily generate conclusions that are 
consistent with Wang and Korth experimental results. 
Data from across all species was used to inform the model. The majority of data is available from 
rabbit preparations, however, key measurements are not recorded in rabbit. Specifically, none of the 
cellular readouts were recorded in rabbit for acute DOX or DOXL and the effect of chronic DOX on 
ICaL was not recorded in rabbit, despite being identified as an important contributor to chronic DOX 
effects on APD. This means there was not a complete species specific data set for any of the drug 
conditions we studied and so we have assumed species differences were small. 
The effects of acute DOX on K+ currents and the consequences in terms of APD alterations are 
contentious issues. The outcomes of modelling are reasonably consistent and predict that acute 
DOX will cause APD prolongation, regardless of whether inhibition of IKr or IKs is the predominant 
effect of DOX on K+ currents. The findings from studies that measure K+ currents are however 
somewhat inconsistent and contradictory. Thus, Wang and Koth (1995) reported that acute DOX 
causes inhibition of IKr, whereas Ducroq et al. (2010) reported that acute DOX inhibits IKs and not 
IKr. In neither study was it possible to infer whether APD effects were the result in whole or part 
from block of either current. When the effect of acute DOX toxicity on K+ currents was modelled 
using the Ducroq et al IC50 values for IKr and IKs (or the IC50 value for IKs alone) there was a 
pronounced increase in APD, an effect more consistent with the consensus reported changes in APD 
compared with when no effect of DOX on IKs was included in the modeling. Unfortunately the 
effect of IKs inhibition on APD in the absence of IKr inhibition  is unclear, with no effect found in 
human (Jost et al., 2005) or rabbit (Lengyel et al., 2001) ventricular myocytes yet, in contrast, APD 
prolongation was found in human and rabbit ventricular myocytes by other investigators (Bosch et 
al., 1998)(Lu et al., 2001). Separately, the simulated effect of IKs inhibition varies from one human 
cardiac myocyte cell model to the next (Mirams et al., 2014) with the ten Tusscher model used in 
the present study exhibiting a far greater APD sensitivity to IKs inhibition than other models. These 
confounding factors mean that it is not possible to conclude if DOX predominantly effects IKs or IKr 
from simulation results alone. Nevertheless, and importantly, varying the specific effect of acute 
DOX on K+ currents did not qualitatively alter our prediction that acute DOX increases SR leak. 
Regardless of the simulated effect of acute DOX on K+ currents (inhibiting IKs only or inhibiting 
both IKs and IKr), for both human and rabbit models the simulated results were closer to 
experimental measurements if SR leak was increased (see online supplement). 
We have made use of only two cardiac myocyte models (rabbit and human) for interpreting our 
results. Others have proposed using species-dependent methods for interpreting pre-clinical data in 
species specific models (O'Hara & Rudy, 2011). However, insufficient data were available for any 
of the compounds we studied to attempt this level of specificity. 
We have assumed that the Hill coefficient is equal to 1 for all targets for both drugs. There are 
limited measurements of the Hill coefficient and cooperative inhibition is a possibility. However, 
Boucek et al., (1987b) did find that the slope of their Dixon plots were for doxorubicin inhibition of 
INaK and IUp, consistent with a Hill coefficient of 1. 
 Finally, we have simulated cellular phenotypes as surrogates for measures of organ scale function. 
Simulating full heart electro-mechanics and pseudo ECGs may provide further insight into the link 
between changes in cellular function and clinical readouts. 
Conclusions 
We have presented the first model to capture the effects of DOX on cardiac electrophysiology and 
Ca2+ handling in the human and the rabbit incorporating acute and chronic effects as well as effects 
of the DOX metabolite DOXL.  The human and rabbit models reproduce qualitative changes in 
APD and Ca2+ concentration morphology. For future reference, our simulations predict three 
important actions of DOX that require confirmation by pharmacological experimentation. These are 
(i) the apparent importance of an hitherto unhearalded increase in SR Ca2+ leak flux, (ii) the 
apparent unimportance of acute DOXL effects on INaCa and (iii) the inference that the increased 
K+ permeability caused by chronic DOX exposure results from an increase in IKr.  
The factorial analysis shows that a limited number of changes to specific channels may explain the 
majority of drug effects on cellular function and that changes in Ca2+ dynamics are caused by DOX 
and DOXL acting directly on Ca2+ handling and are not a secondary effect caused by changes in AP.  
The current modelling approach provides a means of testing the relevance of single target effects in 
determining the cardiotoxic phenotype, and in the case of DOX, emerging information on 
timecourses of effects and drug accumulation in cells can be incorporated to provide refinement and 
greater insight. 
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Table 1. Consensus % change values (𝛼 values) derived using method 1 and method 2 for all currents 
after exposure to DOX and DOXL. 
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Acute DOX 
 𝜶 𝜶  
IRel +60% +78% 29 
13 Rat +43%  
Fractional 
release in % 
10 µM 30min. 37°C 
(Sag et al., 2011) 
0.125  R +96%  Ca2+ release 10 µM 180min. 32°C 
(Mushlin et al., 
1993) 
75 Dog +40%  
Ca2+ release 
(nmol/mg) 
50 µM 2min. 37°C 
(Qing et al., 1991) 
IUp -30% -7% 1289 
210 R -30%  Ca2+ ATPase 90 µM - - 
(Boucek et al., 
1987b) 
2344  
Dog 
-23%  
µM of Ca2+/mg 
of protein/min 
700µM 60min. 37°C 
(Olson et al., 1988) 
967  -42%  
µM of Pi/mg 
of protein/min 
700µM 60min. 37°C 
(Olson et al., 1988) 
1633  -30%  
µM of Pi/mg 
of protein/min 
700 µM Every 30min. 37°C 
(Boucek et al., 
1987b) 
ICaL +40% +32% 217 
58 R +61%  
Peak Ca2+ 
current (pA/pF) 
90 
µM 
120min. 
35-
37°C  
(Earm et al., 1994) 
376 GP 
+21% 
 
Peak Ca2+ 
current (pA/pF) 
100 
µM 
60min. 
35-
36°C  
(Wang & Korth, 
1995) 
INaCa -40% -6% 1581 
4410  
R 
-2%  
Peak NCX 
current (pA/pF) 
90µM 60min. 
35-
37°C  
(Earm et al., 1994) 
319 -22%  
NCX exchange 
rate 
90µM - - 
(Boucek et al., 
1987b) 
14  Dog -85%  
Ca2+ uptake on 
NCX exchanger 
80µM 20 min. 37°C 
(Caroni et al., 1981) 
INaK -20% -1% 7251 
106  Rat -46%  
µM of Pi /mg 
of protein/hr 
90µM 30 min. 35°C 
(Miwa et al., 1986) 
6300  R -10%  
µM of Pi /mg 
of protein/hr 
700 µM 60 min. 37°C 
(Olson et al., 1988) 
9300  
Dog 
-7%  
µM of Pi /mg 
of protein/hr 
700 µM Every 30 min. 37°C 
(Boucek et al., 
1987b) 
13300 -5%  
µM of Pi /mg 
of protein/hr 
700 µM 60 min. 37°C 
(Olson et al., 1988) 
IKr -40% -44% 127 127 GP -44%  
Ik tail current 
(pA) 
100 µM 60 min. 37°C 
(Wang & Korth, 
1995) 
Chronic DOX 
IRel -40% - - - R 
-24%  mRNA  2 mg/kg 8 weeks (1) NA (Huang et al., 2003) 
-29%   1 mg/kg 8 weeks (2) 37°C (Olson et al., 2005) 
-65%   2.5mg/kg 8 weeks (1) 30°C (Arai et al., 1998) 
IUp -10% - - - R 
-26%  
Ca2+ uptake 
(nmol/mg) 
2.5mg/kg 8 weeks (1) 30°C (Arai et al., 1998) 
-7%  1mg/kg 6-9 weeks (2) 30°C (Dodd et al., 1993) 
-11%  1mg/kg 8 weeks (2) 32°C (Olson et al., 2005) 
ICaL +30% - - - Rat +26%  
Peak Ca2+ 
current ( pA/pF) 
2.5mg/kg 10 weeks (2) 
22-
25°C  
(Keung et al., 1991) 
INaCa -20% - - - R 
-13%  mRNA  2.5mg/kg 8 weeks (1) 30°C (Arai et al., 1998) 
-25%  NCX exchanger 1 mg/kg 8 weeks (2) NA (Olson et al., 2005) 
INaK -20% - - - R -15%  nM/mg 1 mg/kg 6-9 weeks (2) 37°C (Dodd et al., 1993) 
IKr +50% - - - R +50%  K+ permeability NA NA NA 
(Shenasa et al., 
1990) 
Acute DOXL 
IRel +0% - 240 240 R +4%  Ca2+ release 10µM 180min. 32°C 
(Mushlin et al., 
1993) 
IUp -60% -56% 8 8 Dog -55%  
Ca2+ loading 
in % of control 
9µM 
Every 
30min. 
25°C 
(Boucek et al., 
1987b) 
ICaL -10% -5% 190 190 GP -5%  
Peak Ca2+ 
current (nA) 
10µM 
15 
min. 
37°C 
(Wang et al., 2001) 
INaCa -100% - - - R -100%  
NCX exchange 
rate 
90µM - - 
(Boucek et al., 
1987b) 
INaK -50% -50% 10 10 Dog -50%  
Na+/K+ ATPase 
in % of control 
10µM 
Every 
30min. 
37°C 
(Boucek et al., 
1987b) 
IKr +50% +48% 11 11  GP +48%  
Ik tail current 
(pA) 
10µM 15min. 37°C 
(Wang et al., 2001) 
Experimental observations (columns 6-10) and average estimates (𝛼 values in column 2) of  changes in ion 
currents generated using method 1 for Na+/K+ pump (INaK), rapid delayed rectifying K+ (IKr), SR Ca2+-ATPase 
pump (IUp), Na+/Ca2+ exchanger (INaCa), the ryanodine receptor (IRel) and the L-type Ca2+ channel (ICaL) after 
acute DOX, chronic DOX and acute DOXL exposure. Extrapolated values of IC50 and EC50 for each dose 
concentration after acute exposure to DOX and DOXL and their average value are also included (columns 4-
5). From these IC50/EC50 values, estimates of change in the currents after exposure to 100 µM of DOX and 10 
µM of DOXL are calculated using method 2 (𝛼 values in column 3). Chronic DOX time of exposure is 
expressed in number of weeks that protocol was applied and the number of doses delivered each weak 
indicated in brackets. Abbreviations: Guinea Pig (GP), Rabbit (R), intracellular calcium concentration 
([Ca2+]i), relaxation time (RT), APD at 90% repolarization (APD90).
Table 2. Consensus values of % change derived using method 1 for APD, systolic Ca2+ concentration 
and Ca2+ relaxation time after exposure to DOX and DOXL. 
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Acute DOX 
APD +50% 142 
61 
GP 
+62%  APD90 100µM 60min. 35-36°C  (Wang & Korth, 1995) 
223 +31%  APD90 100µM 20min. 34-35°C (Wang et al., 2001) 
Ca2+ 
C +50% 92 92 
GP 
+52% [Ca2+]i 
100µM 60min. 35-36°C 
(Wang & Korth, 1995) 
RT +30% 233 233 +30%  [Ca2+]i RT  (Wang & Korth, 1995) 
C -40% 13 13 Rat -43%  [Ca2+]i 10µM 15min. 37°C (Sag et al., 2011) 
Chronic DOX 
APD -20% - - 
R -20%  APD90 0.75mg/kg 6-9weeks (3) 37°C (Shenasa et al., 1990) 
R -23%  APD90 1mg/kg 8 weeks (2) 32°C (Doherty & Cobbe, 1990) 
R +10%  APD90 1.5mg/kg 6 weeks (2) 37°C (Milberg et al., 2007) 
Ca2+ 
C -55% - - Rat 
-  [Ca2+]i 2.5 mg/kg 8 weeks (1) 30°C (Jensen, 1986) 
-55%  [Ca2+]i 2.5 mg/kg 2 weeks (3) 37°C (De Angelis et al., 2010) 
+38%  [Ca2+]i 2 mg/kg 1 week (3) 30°C (Kapelko et al., 1996) 
+74% [Ca2+]i 2.5mg/kg 6 weeks (1) 37°C (Szenczi et al., 2005) 
RT +10% - - Rat 
+20%  [Ca2+]i RT 2.5mg/kg 2 weeks (3) 37°C (De Angelis et al., 2010) 
0%  [Ca2+]i RT 2mg/kg 1 week (3) 30°C (Kapelko et al., 1996) 
Acute DOXL 
APD -30% 30 30  GP -25%  APD90 10 µM 20 min. 34-35°C  (Wang et al., 2001) 
Ca2+ 
C -20% 34 34  
GP 
-23%  [Ca2+]i  
10 µM 15min. 34-35°C  
(Wang et al., 2001) 
RT +50% 92 92  +52% [Ca2+]i RT (Wang et al., 2001) 
 
Experimental observations (columns 5-9) for APD, Ca2+ concentration (Ca2+ C) and relaxation time (Ca2+ RT) 
after acute DOX, chronic DOX and acute DOXL exposure. Column 2 is the average % change estimates of 
changes derived using method 1. Column 3-4 are the extrapolated values of IC50 and EC50 for each dose 
concentration after acute exposure to DOX and DOXL and their average value generated using method 2. 
Chronic DOX time of exposure is expressed in number of weeks that protocol was applied and the number of 
doses delivered each weak indicated in brackets. Two large and opposite changes are reported for acute DOX 
effects on Ca2+ C, both values are reported as the consensus value and these different results are rationalized 
in the body text. Abbreviations: Guinea Pig (GP), Rabbit (R), intracellular calcium concentration ([Ca2+]i), 
relaxation time (RT), APD at 90% repolarization (APD90). 
Table 3. Model predictions of % change in APD, systolic Ca2+ concentration (Ca2+ C) and Ca2+ 
relaxation time (Ca2+ RT) before and after leak is increased. 
 
Acute 100 µM  
DOX 
Acute  
DOX 
Chronic  
DOX 
Acute  
DOXL 
Acute 10 µM  
DOXL 
APD 
Ca2+ 
C 
Ca2+ 
RT 
APD 
Ca2+ 
C 
Ca2+ 
RT 
APD 
Ca2+ 
C 
Ca2+ 
RT 
APD 
Ca2+ 
C 
Ca2+ 
RT 
APD 
Ca2+ 
C 
Ca2+ 
RT 
Rabbit 
𝛼 = 1 
+18% +84% -6% +4% +174% -1% -14% +87% -13% -28% +11% +44% -27% +23% +37% 
Human 
𝛼 = 1 
+12% +90% +10% +15% +141% +41% -1% +84% +17% -32% -14% +13% -30% +6% +7% 
Rabbit 
𝛼 = 2 𝛼 = 4 𝛼 = 4 𝛼 = 10 
+19% +48% +0% +7% +23% +17% -11% -12% +9% -24% -29% +57% -24% -28% +47% 
Human 
𝛼 = 2 𝛼 = 2 𝛼 = 3 𝛼 = 2 
+11% +13% +20% +13% +47% +58% -7% -38% +3% -38% -38% +18% -37% -26% +13% 
Consensus 
% Change 
+50% +50% +30% +50% +50% +30% -20% -55% +10% -30% -20% +50% -30% -20% +50% 
 
Predictions of % change for APD, systolic Ca2+ concentration (Ca2+ C) and Ca2+ relaxation time 
(Ca2+ RT) for acute DOX, chronic DOX, acute DOXL, acute 100 µM DOX and acute 10 µM 
DOXL exposures in rabbit and human models before leak is increased (𝛼 = 1) and after leak is 
increased (𝛼 =  2, 3, 4, 10) and comparison with consensus values for the average % change in 
APD, systolic Ca2+ concentration and Ca2+ relaxation time derived using method 1 (Table 2). 
  
Table 4. Effects of currents on APD, Ca2+ concentration (Ca2+ C) and relaxation time (Ca2+ RT) 
calculated using factorial analysis. 
 Acute 100 µM 
DOX 
Acute DOX Chronic DOX Acute 
DOXL 
Acute 10 µM 
DOXL 
APD IKr 
ICaL 
+6% 
+5% 
IKr 
ICaL 
+5% 
+7% 
IKr 
ICaL 
ILeak 
-6% 
+5% 
-4% 
IKr 
IUp 
INaK 
ILeak 
-7% 
-9% 
-15% 
-6% 
IKr 
IUp 
INaK 
ILeak 
-7% 
-8% 
-14% 
-7% 
Ca2+ C ICaL 
ILeak 
+50% 
-72% 
IUp 
ICaL 
INaCa 
ILeak 
-81% 
+70% 
-67% 
-88% 
ICaL 
ILeak 
+46% 
-109% 
IUp 
INaK 
ILeak 
-113% 
+145
% 
-79% 
IUp 
INaK 
ILeak 
-118% 
+161% 
-87% 
Ca2+ RT ILeak +15% IUp +31% INaCa 
ILeak 
+9% 
+13% 
IUp 
INaK 
ILeak 
+24% 
-13% 
-9% 
IUp 
INaK 
ILeak 
+18% 
-13% 
+9% 
 
  
Table 5: Sensitivity analysis testing model and data assumptions. In each case the derived default 
is the value from the main modelling reported in Results and consensus values derived from 
experiments (data shown in table 4).  
Drug Model Results from Model 
Change in 
APD 
Change in 
Peak Ca2+ 
Change in 
RT50 
Acute DOX Human model Derived default +13% +47% +58% 
  0.5Hz +10% +131% +12% 
  IKr = -30% +11% +45% +58% 
  IKr = -20% +10% +43% +57% 
  IKr = -10% +8% +41% +56% 
  NCX = -10% +13% +17% +23% 
Acute DOX Rabbit model Derived default +7% +23% +17% 
  0.5Hz +24% +3% +49% 
  IKr = -30% +4% +23% +17% 
  IKr = -20% +1% +23% +16% 
  IKr = -10% -1% +23% +16% 
  NCX = -10% +14% +23% +21% 
Acute DOX Consensus values  +50% +50% +30% 
Chronic DOX Human Model Derived default -6% -49% +6% 
  0.5Hz -4% +5% -19% 
  IKr = +25% -3% -36% +4% 
  IKr = 0% +0% -35% +7% 
Chronic DOX Rabbit Model Derived default -11% -12% +9% 
  0.5Hz +6% -40% +52% 
  IKr = +25% -6% -8% +9% 
  IKr = 0% -1% -4% +9% 
Chronic DOX Consensus values  -20% -55% +10% 
Acute DOXL Human Model Derived default -35% -38% +27% 
  0.5Hz -20% +93% -11% 
Acute DOXL Rabbit Model Derived default -24% -29% +57% 
  0.5Hz -12% -45% +122% 
Acute DOXL Consensus values  -30% -20% +50% 
Acute 100 uM DOX Human Model Derived default +11% +13% +20% 
  0.5Hz +9% +4% -20% 
  IKr = -30% +9% +11% +19% 
  IKr = -20% +8% +9% +19% 
  IKr = -10% +6% +7% +19% 
  NCX = -10% +11% +18% +20% 
  IKs=-95%, IKr no effect +71% +102% +43% 
  IKs=-95%, IKr =-50% +111% +150% +46% 
Acute 100 uM DOX Rabbit Model Derived default +19% +48% +0% 
  0.5Hz +31% +33% +11% 
  IKr = -30% +14% +41% +1% 
  IKr = -20% +11% +37% +1% 
  IKr = -10% +8% +33% +1% 
  NCX = -10% +18% +51% -1% 
  IKs=-95%, IKr no effect +12% +40% +0% 
  IKs=-95%, IKr =-50% +33% +68% -1% 
Acute 100 uM DOX Consensus values  +50% +50% +30% 
Acute 10 uM DOXL Human Model Derived default -37% -26% +2% 
  0.5Hz -19% +104% -15% 
Acute 10 uM DOXL Rabbit Model Derived default -24% -28% +47% 
  0.5Hz -6% -44% +105% 
Acute 10 uM DOXL Consensus values  -30% -20% +50% 
Figure 1. Rabbit and human models: changes in APD and Ca2+ concentration for acute DOX, chronic 
DOX, acute DOXL, acute 100 µM DOX and acute 10 µM DOXL before (red dashed line) and after 
leak increase (blue dash-dotted line) with respect to the corresponding control model with no drug 
effects (black solid line). 
Figure 2. Simulated caffeine exposure in the human model. The red dashed line shows the predicted 
INaCa current following a simulated caffeine exposure with no change in INaCa but with inhibition of 
INaK by 50%. The black line shows the simulated INaCa current following a simulated caffeine exposure 
using the reference model. 
Figure 3. Effect of currents on APD, systolic Ca2+ concentration and Ca2+ relaxation time for (left) 
acute DOX model derived at 100 µM (centre) acute DOX, chronic DOX and acute DOXL models 
obtained at a range of experimental dosages and (right) acute DOXL model derived at 10 µM.  
Figure 4. Comparison between rabbit and human models. Panels A-E show results with no change 
in SR leak and panels F-J show results after SR leak is optimised for changes in APD, Ca2+ 
concentration (Ca2+ C) and Ca2+ relaxation time (Ca2+ RT) for acute DOX, chronic DOX, acute 
DOXL, acute 100 µM DOX and acute 10 µM DOXL. 
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